Actively Recruiting
Para-aortic Lymph Node Metastasis in Resectable Pancreatic Cancer
Led by Jon Unosson · Updated on 2023-10-04
300
Participants Needed
6
Research Sites
261 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Lymph node metastases are a strong prognostic predictor for pancreatic cancer. Para-aortic lymph nodes (PALN) are the final nodes for periampullary cancers before the cancer cells enter the systemic lymphatic circulation. Some consider these nodes to be regional lymph nodes and dissect them as a part of a routine lymphadenectomy for pancreatic cancer. Others argue that metastases to these nodes represent systemic disease and recommend that radical surgery including extended lymphadenectomy should be abandoned. The aim of this study is to define the incidence and clinical consequences of PALN metastasis in patients submitted to a tentative curative resection for carcinoma of the head of the pancreas by systematically resecting paraaortic lymph nodes. Primary outcome 1\) To determine incidence of PALN metastasis in patients submitted to a tentative curative resection Secondary outcomes 1. To determine prognosis of patients with PALN metastasis after a curative resection 2. To determine incidence of metastasis in reginal lymph nodes in patients submitted to a tentative curative resection. 3. To determine prognosis of patients with metastasis in regional lymph nodes in patients submitted to a tentative curative resection. 4. To address the question of how to optimize the frozen section analyses of PALN as related to the final pathology report. 300 patients are planned to be included in the trial.
CONDITIONS
Official Title
Para-aortic Lymph Node Metastasis in Resectable Pancreatic Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Resectable suspected periampullary cancer requiring duodenopancreatectomy according to NCCN 2020 guidelines
- Borderline resectable periampullary cancer requiring duodenopancreatectomy according to NCCN 2020 guidelines
- Age over 18 years
- Written patient consent
You will not qualify if you...
- Contraindication for a radical resection procedure
- Unresectable tumor or metastatic disease according to NCCN 2020 guidelines
- Mental or organic disorders interfering with informed consent or treatment
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 6 locations
1
Odense University Hospital
Odense, Denmark
Not Yet Recruiting
2
Sahlgrenska university hospital
Gothenburg, Sweden
Active, Not Recruiting
3
Linköping University Hospital
Linköping, Sweden
Active, Not Recruiting
4
Skåne University Hospital
Lund, Sweden
Active, Not Recruiting
5
Norrland University Hospital
Umeå, Sweden
Actively Recruiting
6
Uppsala University Hospital
Uppsala, Sweden, 75653
Actively Recruiting
Research Team
C
Christopher Månsson
CONTACT
B
Britt-Marie Karlson
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here